In contrast, immunocompetent in vivo studies with combinatorial therapies have been performed in melanoma, pancreatic neuroendocrine tumors, metastatic breast, and small cell lung cancer [79,80], highlighting that ovarian cancer research is lacking in uncovering the mechanistic interplay between anti-angiogenic and PD-1-based therapy. This evidence concerns the gene PDCD1 and ovarian carcinoma.